B. Riley reiterated their buy rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) in a research note released on Thursday, Benzinga reports. They currently have a $10.00 price target on the stock. Several other equities research analysts have also issued reports on FUSN. Morgan Stanley dropped their price objective on Fusion Pharmaceuticals from […]
B. Riley reaffirmed their buy rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) in a research report report published on Thursday, Benzinga reports. They currently have a $10.00 price objective on the stock. A number of other brokerages also recently issued reports on FUSN. Morgan Stanley cut their price objective on shares of […]
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have earned an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay’s lead program includes FPI-1434, […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) CEO John Valliant sold 11,994 shares of Fusion Pharmaceuticals stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $6.41, for a total transaction of $76,881.54. Following the transaction, the chief executive officer now directly owns 328,130 shares in […]